广发创新药ETF联接C(012738)利润分配表
| |
2025-12-31 |
2025-06-30 |
2024-12-31 |
2024-06-30 |
| 收入 |
93,184,903.44 |
103,040,927.26 |
-136,566,863.41 |
-220,872,741.58 |
| 利息合计 |
218,782.45 |
89,770.64 |
160,275.61 |
77,575.45 |
| 其中:存款利息收入 |
218,782.45 |
89,770.64 |
160,275.61 |
77,575.45 |
| 债券利息收入 |
- |
- |
- |
- |
| 资产支持证券利息收入 |
- |
- |
- |
- |
| 买入返售金融资产收入 |
- |
- |
- |
- |
| 投资收益合计 |
-27,628,670.09 |
-33,465,908.77 |
-82,297,837.82 |
-53,390,682.88 |
| 其中:股票投资收益 |
740,209.06 |
-442,496.44 |
-6,748,053.44 |
-3,629,202.17 |
| 基金投资收益 |
-28,523,321.93 |
-33,130,163.62 |
-75,943,429.85 |
-50,020,984.98 |
| 债券投资收益 |
35,709.57 |
- |
5,724.73 |
1,342.46 |
| 资产支持证券投资收益 |
- |
- |
- |
- |
| 衍生工具收益 |
- |
- |
- |
- |
| 股利收益 |
118,733.21 |
106,751.29 |
387,920.74 |
258,161.81 |
| 基金分红收益收益 |
- |
- |
- |
- |
| 公允价值变动收益 |
119,141,136.04 |
136,147,646.88 |
-54,838,489.61 |
-167,699,631.19 |
| 其他收入 |
1,453,655.04 |
269,418.51 |
409,188.41 |
139,997.04 |
| 费用 |
1,880,742.69 |
791,875.84 |
1,626,064.78 |
829,219.32 |
| 管理人报酬 |
285,485.16 |
131,345.78 |
325,165.22 |
174,930.66 |
| 基金托管费 |
57,096.99 |
26,269.12 |
65,033.09 |
34,986.13 |
| 销售服务费 |
1,353,381.00 |
544,272.67 |
1,057,682.33 |
530,475.12 |
| 交易费用 |
- |
- |
- |
- |
| 利息支出 |
7,383.58 |
- |
- |
- |
| 其中:卖出回购金融资产支出 |
7,383.58 |
- |
- |
- |
| 其他费用 |
177,395.96 |
89,988.27 |
178,184.14 |
88,827.41 |
| 利润总额 |
91,304,160.75 |
102,249,051.42 |
-138,192,928.19 |
-221,701,960.90 |
欢迎访问证券之星!请点此与我们联系 版权所有: Copyright © 1996-年